Xintao Qiu

Nov 20, 2024 | cell.com | Marco Seehawer |Zheqi Li |Triet M. Bui |Pierre Foidart |Jun Nishida |Clive S. D’Santos | +18 more

ResultsBoth KDM5A and KDM5B were reported to be amplified and overexpressed in breast cancer.7,14 However, paralog-specific differences between luminal and basal breast cancer have not been analyzed. Thus, we assessed the mutational landscape of KDM5 paralogs in luminal A (LumA) and basal breast tumors in the TCGA cohort.

Dec 14, 2023 | nature.com | Paolo Tarantino |Ana C. Garrido-Castro |Brittany L. Bychkovsky |Lynette M. Sholl |Matthew Meyerson |Rinath Jeselsohn | +5 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-023-43324-w, published online 18 November 2023In this article, the author names Paolo Tarantino, Hersh Gupta, Melissa E. Hughes, Janet Files, Sarah Strauss, Gregory Kirkner, Anne-Marie Feeney, Yvonne Li, Ana C. Garrido-Castro, Romualdo Barroso-Sousa, Brittany L. Bychkovsky, Simona DiLascio, Lynette Sholl, Laura MacConaill, Neal Lindeman, Bruce E. Johnson, Matthew Meyerson, Rinath Jeselsohn, Xintao Qiu, Rong Li, Henry Long, Eric P.

Dec 4, 2023 | nature.com | Shahabbedin Sotudian |Xintao Qiu |Renee Maria Saliby |Rong Li |Cindy H Chau |James A. DeCaprio | +14 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02605-z, published online 21 October 2023. This article was originally published under a standard Springer Nature license (© The Author(s), under exclusive licence to Springer Nature America, Inc.); it is now available as an open-access paper under a Creative Commons Attribution 4.0 International license, © The Author(s). The error has been corrected in the HTML and PDF versions of the article.

Oct 21, 2023 | nature.com | Xintao Qiu |Renee Maria Saliby |Rong Li |Cindy H Chau |James A. DeCaprio |William D Figg | +14 more

AbstractAlthough circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical decisions in cancer care, they have limited ability to identify the transcriptional programs that govern cancer phenotypes and their dynamic changes during the course of disease. To address these limitations, we developed a method for comprehensive epigenomic profiling of cancer from 1 ml of patient plasma.